РУКОВОДСТВО ПО ОБЩЕСТВУ

FDA Predetermined Change Control Plans for AI Devices

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.

Прослушайте это руководствоОзвучено ИИ · ~3 min

На этой странице3 минуты чтения
  1. Обзор
  2. Глубокое погружение
  3. Реальная реализация
  4. The Future of FDA Predetermined Change Control Plans for AI Devices
  5. Применение на практике
  6. Продолжайте исследовать
  7. Часто задаваемые вопросы

Обзор

FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Глубокое погружение

A PCCP is a planned change-management component of a medical-device marketing submission. FDA’s August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to “retrain as needed” do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDA’s current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.

Реальная реализация

A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.

A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.

A change to a model’s intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.

A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.

The Future of FDA Predetermined Change Control Plans for AI Devices

FDA’s guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the device’s update method changes.

Применение на практике

Почему это важно

  • Риски и безопасность. Катастрофический и повседневный вред ИИ зависит от того, кто понимает риски и может действовать.
  • Более четкие решения. Общественная и профессиональная грамотность определяет, возможна ли с политической точки зрения сильная политика безопасности.
  • Пробивая шумиху. Четкие объяснения уменьшают влияние шумихи, лабораторного пиара и расплывчатого этического театра.

Следите за

  • Относитесь к экзистенциальному риску как к научной фантастике, в то время как возможности растут.
  • Сбивает с толку безопасность поверхности продукта и выравнивание при высокой автономности.
  • Оставляя неанглоязычную и неспециалистскую аудиторию только с некачественными источниками.

Следующие шаги

  1. Отдельные риски повреждения продукта, неправильного использования и потери контроля/перекоса.
  2. Спросите, какие доказательства могут изменить ваше мнение о сроках и серьезности.
  3. Предпочитайте первоисточники и конкретные оценки маркетинговым заявлениям.
  4. Определите один путь действий: карьера, политика, финансирование или навыки, а не только осведомленность.

Продолжайте исследовать

Бесплатная рассылка

Получайте ежедневный AI-обзор

Три проверенных AI-истории каждое утро буднего дня, написанные простым английским. Бесплатно навсегда, без рекламы.

Одно электронное письмо каждый будний день. Отписаться в один клик. Мы никогда не продаем и не передаем ваш адрес.

Проверьте себя

Take the FDA Predetermined Change Control Plans for AI Devices quiz

Мгновенная обратная связь по каждому ответу и общий сертификат с проверяемым идентификатором после прохождения курса.

Начать тест

Поддержите бесплатное образование в области искусственного интеллекта. AI Understanding — это некоммерческая организация 501(c)(3). Никакой рекламы и платного доступа. Сделать пожертвование

Часто задаваемые вопросы

What is FDA Predetermined Change Control Plans for AI Devices?

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Which three elements form the core of an AI-device PCCP?

FDA’s final guidance describes planned modifications, a protocol for implementing them, and an assessment of their impact.

When does FDA review a proposed PCCP?

FDA reviews the PCCP as part of the relevant marketing submission.

What does PCCP authorization allow a manufacturer to do?

The plan can support specified future modifications without a new marketing submission for each change, if they follow the authorized plan.

A manufacturer wants to add a new patient population that its PCCP did not describe. What is the appropriate next step?

A change outside the authorized scope needs a regulatory assessment and may require a new submission.

Which version of FDA’s AI-device PCCP guidance is final?

FDA identifies its tailored final guidance as issued in August 2025.

Продолжайте учиться

Связанные руководства

Другие руководства, выбранные по этой теме

Получите бесплатный AI-сертификатКороткий бесплатный курс и экзамен. Без стоимости, без карты. Около 2,5 часов.Начать бесплатно →